Key statistics
On Thursday, Biontech SE (BNTXN:MEX) closed at 2,090.41, -12.57% below its 52-week high of 2,391.00, set on Sep 13, 2024.
52-week range
Open | 2,140.00 |
---|---|
High | 2,140.00 |
Low | 2,090.41 |
Bid | 2,088.01 |
Offer | 2,390.00 |
Previous close | 2,090.41 |
Average volume | 77.75 |
---|---|
Shares outstanding | 237.77m |
Free float | 214.95m |
P/E (TTM) | -- |
Market cap | 26.70bn USD |
EPS (TTM) | -2.34 USD |
Data delayed at least 20 minutes, as of Sep 19 2024 20:05 BST.
More ▼
- Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European Union
- Pfizer und BioNTech erhalten positive CHMP-Empfehlung für an Omikron KP.2 angepassten COVID-19-Impfstoff in der Europäischen Union
- EQS-News: MIG Capital portfolio company Inbolt raises €15 million in Series A to further develop AI-powered 3D vision in robots
- BioNTech to Host AI Day as an Edition of its Innovation Series on October 1, 2024
- BioNTech veranstaltet am 1. Oktober 2024 „AI Day“ als eine Ausgabe der „Innovation Series“
- BioNTech to Present Clinical Data Updates Across mRNA and Immunomodulatory Oncology Portfolio at ESMO Congress 2024
- BioNTech präsentiert auf dem ESMO-Kongress 2024 klinische Daten-Updates aus dem mRNA und immunmodulatorischen Onkologie-Portfolio
- Pfizer and BioNTech Receive U.S. FDA Approval & Authorization for Omicron KP.2-adapted COVID-19 Vaccine
- Pfizer und BioNTech geben Update zu mRNA-basiertem Kombinationsimpfstoffprogramm gegen Grippe und COVID-19 bei Personen im Alter von 18 bis 64 Jahren bekannt
- Pfizer and BioNTech Provide Update on mRNA-based Combination Vaccine Program Against Influenza and COVID-19 in Individuals 18-64 Years of Age
More ▼